# Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Source: https://onco.cc/trials/nct05951179/  
OnCo record `nct05951179` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TARA-002 in bladder & urothelial cancer, run by Protara Therapeutics, now recruiting.

## Summary

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer is a phase 2 interventional study registered as NCT05951179 by Protara Therapeutics, with 131 participants planned, started 2023-09-15 and due to reach its primary completion in 2031-10. Interventions recorded: TARA-002.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05951179
- Phase: 2
- Setting: A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer
- Sponsor: Protara Therapeutics
- Enrolled: 131

## Sources

- ClinicalTrials.gov NCT05951179: https://clinicaltrials.gov/study/NCT05951179

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [TARA-002](https://onco.cc/drugs/tara-002/)
- companies: [Protara Therapeutics](https://onco.cc/companies/protara-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05951179.json